{"classes":[{"categories":[{"measurements":[{"comment":"Lower limit of 95% CI were not estimable due to insufficient number of events.","groupId":"OG000","lowerLimit":"22.05","upperLimit":"NA","value":"25.56"},{"comment":"Lower limit of 95% CI were not estimable due to insufficient number of events.","groupId":"OG001","lowerLimit":"22.77","upperLimit":"NA","value":"28.19"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"259"},{"groupId":"OG001","value":"263"}],"units":"Participants"}],"description":"OS was defined as the time from the date of randomization to the date of the participant's death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received daratumumab intravenous infusion (Dara IV) 16 milligrams per kilogram (mg/kg) once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks thereafter until disease progression, unacceptable toxicity, withdrawal of consent, the investigator decides to stop treatment, or the start of subsequent anticancer therapy. The duration for each cycle was 28 days.","id":"OG000","title":"Daratumumab IV"},{"description":"Participants received daratumumab 1800 mg subcutaneous injection (Dara SC) co-formulated with recombinant human hyaluronidase (rHuPH20) 2000 Units per milliliter (U/mL), once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks thereafter until disease progression, unacceptable toxicity, withdrawal of consent, the investigator decides to stop treatment, or the start of subsequent anticancer therapy. The duration for each cycle was 28 days.","id":"OG001","title":"Daratumumab SC"}],"paramType":"MEDIAN","populationDescription":"ITT population included all the randomized participants.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}